Unilife, Stason Pharma Sign Agreement For Unitract 1mL Safety Syringe

The agreement includes a requirement for Stason to purchase a minimum of one million units of the Unitract 1mL syringe per year during the term of the contract (subject to annual review).

Other countries within South-East Asia may be added to the list of designated territories where Stason has exclusive rights to sell the Product if the parties reach agreement on minimum orders for those countries.

The Unitract range of 1mL syringes allows operators to control the speed of automatic needle retraction directly from the patient’s body into the barrel of the syringe where it is locked in place. The products will help prevent the transmission of blood-borne diseases such as HIV and hepatitis C via aerosol dispersal, needlestick injuries and syringe reuse. Primary target markets of the products include healthcare facilities, pharmaceutical companies and patients who self-administer prescription medication.

Also, while Unilife continues to have a relationship with Shanghai Kindly Enterprise Development Group (KDL) for the assembly of its Unitract 1mL syringes within China on a per order basis, other agreements between Unilife and KDL relating to the distribution of the product within China and other agreed territories have expired. Stason has advised the company of a preference to receive units of the Unitract 1mL syringe that are assembled at Unilife’s FDA-registered facilities in the US State of Pennsylvania.

Harry Fan, CEO of Stason, said: “We believe strongly in the market for the Unitract safety syringe and its potential to help decrease needlestick injuries around the world. We are excited to be one of the first distributors of this revolutionary device and to have the opportunity to exclusively distribute the Unitract syringe to our customers in Asia. In particular, we believe there are significant opportunities for pharmaceutical companies to gain a competitive market advantage by supplying their injectable drugs in kits containing the drug vial and units of the Unitract 1mL Syringe.”

Diana Wood, VP of corporate development, said: “This strategic alliance with Unilife also represents our joint vision where drugs and devices come together to deliver medications more comfortably to patients and more safely for hospital staff.”

Alan Shortall, CEO of Unilife, said: “With manufacturing of our Unitract 1mL syringes underway at our FDA-certified facility in Pennsylvania, we are excited to move forward with this initial distribution agreement and initial order for one million Unitract safety syringes with Stason Pharmaceuticals and Standard Chem and Pharma. We believe there is a significant market opportunity for our safety syringes throughout the Asia-Pacific region, especially within fast-growing nations where there is both an appreciation for innovative US-manufactured technology and a desire to use premium safety medical devices which can minimize the transmission of blood-borne pathogens such as HIV and hepatitis C within healthcare facilities.

“We look forward to working closely with Stason and Standard to develop these markets and secure sustained rates of growth for the sale of our products across Asia. We are also continuing to negotiate with other pharmaceutical and healthcare companies across the world for distribution rights for the Unitract 1mL syringes. We expect that additional agreements will be signed in conjunction with the continued global rollout of the Unitract 1mL syringes.”

Unilife is a US-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication.

Stason Pharma is a California-based pharma company involved in drug development, manufacturing, importation exportation and the licensing and marketing of both generic and branded products.